The Lupus Multiplex Registry and Repository is finding the genes that cause lupus (also known as SLE or Systemic Lupus erythematosus). It works with families with one or more living lupus patients from across the US, Canada, Puerto Rico and the Virgin Islands, utilizing the genetic link between blood relatives to locate responsible genes.
Cassion Biotech has developed a bio-superior drug delivery system, HEPylation ? System, which uses a patented composition designed to improve the performance of many powerful drug compounds in terms of safety, tolerability, efficacy, and quality.
GG Companies develops a powerful arthritis rub, a topical herbal gel used to soothe painful areas.
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
Tetherex is developing a treatment for inflammatory and thrombotic diseases such as Crohn’s disease. Preclinical studies have shown a positive impact in remission of the disease with evidence of potentially reversing the disease process.
Otologic Pharmaceutics, Inc. is an organization formed specifically to commercialize promising technologies that address novel pharmacological solutions for hearing and balance health.
Ecolab Inc. (Ecolab) develops and markets products and services for the hospitality, foodservice, healthcare and industrial markets.
Kupiec Group is a consortium of scientific?professionals specializing?in pharmaceutical, genetic and forensic fields that provide knowledge-based?expert services to the legal and risk?management communities.
Choncept?s scientific innovation is focused on development of new technology to produce chondroitin from fermentation of recombinant bacteria to replace the current chondroitin source of beef and other animal by-products.
EpimedX, LLC is a biotechnology company that was founded in 2011 with the mission to develop Gene Regulation Therapy? ? a promising technology that is expected to provide a safe, cost-effective, and permanent treatment for sickle cell disease, beta-thalassemia, and malaria without dangerous or harmful side effects.
Astellas is an international pharmaceutical company intensely focused on five key therapeutic areas: cardiology, dermatology, immunology, infectious disease, and urology.
IPS Research Company provides phase 1-4 inpatient and outpatient clinical trials. IPS Research specializes in clinical drug trials dealing with psychiatric disorders, including Depression, Schizophrenia, Bipolar Depression, ADHD, GAD, PTSD, Dementia, Alzheimer?s Disease, Child Depression and a variety of Anxiety Disorders.
Heparinex is a biotechnology company focused on the development of novel recombinant synthesis of heparinoid compounds for various markets including anticoagulation, biomaterials, and cellular modulation applications.
Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.
Analytical testing laboratory that provides innovative methodologies for greater flexibility and higher throughput for data collection needs.
AstraZeneca is a global innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.
Respiron is developing an antiviral drug, RN-1, to treat any existing and emerging strains of influenza virus. It can potentially cure flu symptoms in nearly 300 million people worldwide regardless of virus mutation.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
Selexys is a development stage biopharmaceutical company focused on the treatment of inflammatory and thrombotic diseases. ?The company has developed antibodies that block recruitment of white blood cells to activated endothelium and platelets. ?
Sensuli, LLC is developing a true once-a-day glucose-responsive insulin that may mimic a healthy human pancreas. Sensulin? may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.